Meeting
2021 ASCO Annual Meeting
TIVO-3: Durability of response and updated overall survival of tivozanib versus sorafenib in metastatic renal cell carcinoma (mRCC).
Authors
Elena Verzoni
Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
Elena Verzoni , Bernard Escudier , Thomas E. Hutson , David F. McDermott , Sumanta K. Pal , Camillo Porta , Brian I. Rini , Michael N. Needle , Michael B. Atkins
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT02627963
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4546)
DOI
10.1200/JCO.2021.39.15_suppl.4546
Abstract #
4546
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Estimated cost of adverse event (AE) management for patients (pts) with metastatic renal cell carcinoma (mRCC) treated with a VEGFR TKI.
First Author: Jeffrey Thomas Yorio
Poster
2022 ASCO Genitourinary Cancers Symposium
Tivozanib (T) as first-line (1L) treatment of metastatic renal cell carcinoma (mRCC): A real-world outcome review in North-West of England (NWE), UK.
First Author: Jonathan Heseltine
Poster
2020 ASCO Virtual Scientific Program
TIVO-3: Final OS analysis of a phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with metastatic renal cell carcinoma (RCC).
First Author: Sumanta K. Pal
Poster
2020 Genitourinary Cancers Symposium
Tivozanib as first-line treatment of metastatic renal cell carcinoma: A real-world outcome review in North-West of England, United Kingdom.
First Author: Sam Wong